PUMA BIOTECHNOLOGY, INC. (PBYI)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch PBYI
See up to 3 months of PBYI. The 7-day demo opens the 1M and 3M ranges and puts PBYI on your watchlist.
Start 7-day demoLatest PBYI insider trades
About PUMA BIOTECHNOLOGY, INC. (PBYI)
The SEC lists PUMA BIOTECHNOLOGY, INC. under CIK 0001401667, in pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
PBYI Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 67,150 | $612K |
| Option exercise | 2 | 100,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
PBYI insider transactions (Form 4)
3623 Form 4 filings on record, the earliest from Jun 11, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Troy Edward Wilson - Director | Open-market sale | Common Stock | 5,000 | $9.10 | $46K | |
| Alessandra Cesano - Director | Option exercise | Common Stock | 50,000 | $2.93 | $147K | |
| Alessandra Cesano - Director | Open-market sale | Common Stock | 62,150 | $9.12 footnote F2 | $567K | |
| Alessandra Cesano - Director | Option exercise | Stock Option | 50,000 | $0.00 | - | |
| ||||||
| Alan H. Auerbach - Officer | Open-market sale | Common Stock | 44,058 | $8.26 | $364K | |
 Douglas M. Hunt - Officer | Open-market sale | Common Stock | 8,460 | $8.26 | $70K | |
 Maximo F. Nougues - Officer | Open-market sale | Common Stock | 9,386 | $8.26 | $78K | |
| Troy Edward Wilson - Director | Grant or award | Common Stock | 27,000 | $0.00 footnote F1 | - | |
| Troy Edward Wilson - Director | Open-market sale | Common Stock | 10,800 | $7.20 footnote F3 | $78K | |
| ||||||
| Brian M. Stuglik - Director | Grant or award | Common Stock | 27,000 | $0.00 footnote F1 | - | |
| Brian M. Stuglik - Director | Open-market sale | Common Stock | 8,100 | $7.20 footnote F3 | $58K | |
| ||||||
 Adrian Senderowicz - Director | Grant or award | Common Stock | 27,000 | $0.00 footnote F1 | - | |
| Adrian Senderowicz - Director | Open-market sale | Common Stock | 27,000 | $7.20 footnote F3 | $194K | |
| ||||||
| Michael Patrick Miller - Director | Grant or award | Common Stock | 27,000 | $0.00 footnote F1 | - | |
| ||||||
 Jay M. Moyes - Director | Grant or award | Common Stock | 27,000 | $0.00 footnote F1 | - | |
| Jay M. Moyes - Director | Open-market sale | Common Stock | 22,000 | $7.22 footnote F3 | $159K | |
| ||||||
| Allison Dorval - Director | Grant or award | Common Stock | 27,000 | $0.00 footnote F1 | - | |
| Allison Dorval - Director | Open-market sale | Common Stock | 11,610 | $7.20 footnote F3 | $84K | |
| ||||||
| Alessandra Cesano - Director | Grant or award | Common Stock | 27,000 | $0.00 footnote F1 | - | |
| ||||||
| Alan H. Auerbach - Officer | Grant or award | Common Stock | 159,778 footnote F1 | $0.00 footnote F1 | - | |
| Alan H. Auerbach - Officer | Grant or award | Stock Option (Right to Buy) | 227,474 | $0.00 | - | |
| ||||||
| Douglas M. Hunt - Officer | Grant or award | Common Stock | 49,394 footnote F1 | $0.00 footnote F1 | - | |
| Douglas M. Hunt - Officer | Grant or award | Stock Option (Right to Buy) | 70,321 | $0.00 | - | |
| ||||||
| Maximo F. Nougues - Officer | Grant or award | Common Stock | 46,739 footnote F1 | $0.00 footnote F1 | - | |
| Maximo F. Nougues - Officer | Grant or award | Stock Option (Right to Buy) | 66,541 | $0.00 | - | |
| ||||||
| Michael Patrick Miller - Director | Open-market sale | Common Stock | 20,000 | $4.86 footnote F1 | $97K | |
| ||||||
| Alessandra Cesano - Director | Open-market sale | Common Stock | 27,000 | $3.37 | $91K | |
| Maximo F. Nougues - Officer | Open-market sale | Common Stock | 5,587 | $3.53 | $20K | |
| Maximo F. Nougues - Officer | Open-market sale | Common Stock | 3,935 | $3.54 | $14K | |
| Douglas M. Hunt - Officer | Open-market sale | Common Stock | 4,374 | $3.53 | $15K | |
| Douglas M. Hunt - Officer | Open-market sale | Common Stock | 3,443 | $3.54 | $12K | |
| Alan H. Auerbach - Officer | Open-market sale | Common Stock | 25,592 | $3.53 | $90K | |
| Alan H. Auerbach - Officer | Open-market sale | Common Stock | 21,580 | $3.54 | $76K | |
| Jay M. Moyes - Director | Open-market sale | Common Stock | 22,000 | $3.40 | $75K | |
| Michael Patrick Miller - Director | Grant or award | Common Stock | 27,000 | $0.00 | - | |
| Jay M. Moyes - Director | Grant or award | Common Stock | 27,000 | $0.00 | - | |
Item 2.02, 9.01
Item 5.07
Item 2.02, 9.01
Item 2.02, 9.01
Recent PBYI Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| WILSON TROY EDWARD | Director | 5,000 | $46K | View on EDGAR | |
| Cesano Alessandra | Director | 62,150 |
PBYI insider trading FAQ
What is the latest insider trade for PBYI?
PUMA BIOTECHNOLOGY, INC. (PBYI) had 2 insider filings in the last 90 days, with the most recent on 2026-09-17. The full record for PBYI runs to 23 Form 4 filings, the earliest from 2025-06-11. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying PBYI stock?
No insider purchases of PBYI were filed in the last 90 days.
How many insiders are selling PBYI stock?
2 insider sales of PBYI were filed in the last 90 days, totaling $612K.
Where can I see PBYI SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects PBYI Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Troy Edward Wilson view on EDGAR
- - Alessandra Cesano view on EDGAR
- - Alan H. Auerbach view on EDGAR
- - Douglas M. Hunt view on EDGAR
- - Maximo F. Nougues view on EDGAR
- - Troy Edward Wilson view on EDGAR
- - Brian M. Stuglik view on EDGAR
- - Adrian Senderowicz view on EDGAR
- - Michael Patrick Miller view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where PBYI's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow PBYI with a 7-day demo
- PBYI on your watchlist
- Every PBYI Form 4 filing on record
- Up to 3 months of PBYI price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
